Overview

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-11-07

Target enrollment:

Participant gender:

Summary

The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

BioInvent International AB

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

pembrolizumab